October 29th 2024
The outcomes of the EMBARK and CIFFREO trials in boys aged 4 to 7 have raised concerns in the Duchenne muscular dystrophy (DMD) community and prompted layoffs at Pfizer.
October 28th 2024
September 26th 2024
FDA Extends Review Time for Investigational Duchenne Agent Givinostat
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
Balancing Hopes for a Cure for SMA, DMD With Realistic Expectations